GFPT2 drives sunitinib resistance of renal cell carcinoma via enzyme-dependent and -independent manners - PubMed
3 days ago
- #GFPT2
- #Renal cell carcinoma
- #Sunitinib resistance
- GFPT2 drives sunitinib resistance in renal cell carcinoma (RCC) through enzyme-dependent and -independent mechanisms.
- Elevated glutamine levels and GFPT2 upregulation are linked to reduced sunitinib sensitivity in RCC.
- GFPT2 modulates O-GlcNAcylation, enhancing YAP1 stability and nuclear translocation, contributing to drug resistance.
- GFPT2 interacts with KEAP1, reducing NRF2 degradation and dysregulating antioxidant gene transcription, promoting resistance.
- Targeting GFPT2's non-metabolic functions may improve sunitinib sensitivity in RCC treatment.